Search results for " anthracycline"

showing 7 items of 7 documents

Citrus sinensis and Vitis vinifera Protect Cardiomyocytes from Doxorubicin-Induced Oxidative Stress: Evaluation of Onconutraceutical Potential of Veg…

2020

Abstract: The interest towards nutraceuticals able to counteract drug side effects is continuously growing in current chemotherapeutic protocols. In the present study, we demonstrated that smoothies containing mixtures of Citrus sinensis and Vitis vinifera L. cv. Aglianico N, two typical fruits of the Mediterranean diet, possess bioactive polyphenols that protect cardiomyocytes against doxorubicin-induced oxidative stress. The polyphenolic extracts isolated from Citrus sinensis- and Vitis vinifera-based functional smoothies were deeply characterized by Liquid Chromatography-Mass Spectrometry methods. Subsequently, the functional smoothies and relative mixtures were tested to verify their ab…

0301 basic medicineonconutraceuticalPhysiologyClinical BiochemistrycardiotoxicityAnthracyclinemedicine.disease_causeBiochemistryArticle03 medical and health sciences0302 clinical medicineNutraceuticalmedicineoxidative stressDoxorubicinFood scienceVitis viniferaadjuvant therapy; anthracyclines; antioxidants; apoptosis; cardiotoxicity; functional foods; onconutraceutical; oxidative stress; polyphenolsMolecular Biologypolyphenolsfunctional foodsanthracyclinesChemistryFunctional foodlcsh:RM1-950apoptosisApoptosifood and beveragesadjuvant therapyCell Biology030104 developmental biologyantioxidantslcsh:Therapeutics. PharmacologyApoptosisPolyphenol030220 oncology & carcinogenesisOxidative streBreast cancer cellsAntioxidantCitrus × sinensisOxidative stressmedicine.drugAntioxidants
researchProduct

Timely recognition of cardiovascular toxicity by anticancer agents: a common objective of the pharmacologist, oncologist and cardiologist.

2011

Both conventional and new anticancer drugs can frequently cause adverse cardiovascular effects, which can span from subclinical abnormalities to serious life-threatening and sometimes fatal events. This review examines the principal basic and clinical elements that may be of profit to identify, prevent and treat such toxicities. Clearly, the accomplishment of such objectives requires the strong commitment and cooperation of different professional figures including, but not limited to, pharmacologists, oncologists and cardiologists. The aspect of anticancer drug cardiotoxicity seems to be somehow underestimated, mainly due to inadequate reporting of adverse reactions from oncology drugs in t…

Cardiovascular toxicityTime FactorsSettore MED/06 - Oncologia MedicaPharmacology toxicologyCardiologyAntineoplastic AgentsPharmacologyToxicologyMedical OncologyCardiotoxinsCardiovascular SystemProfessional RolePharmacovigilanceMedicineAnimalsHumansPhysician's RoleMolecular BiologyPharmacologyCardiotoxicitybusiness.industryCardiovascular toxicity Anthracyclines Tyrosine kinase inhibitors TrastuzumabSettore MED/11 - Malattie Dell'Apparato CardiovascolareAnticancer drugLaboratory PersonnelCardiovascular DiseasesSettore BIO/14 - FarmacologiaCardiology and Cardiovascular MedicinebusinessOncology drugsCardiovascular toxicology
researchProduct

Pathophysiology of anthracycline cardiotoxicity.

2016

Anthracyclines (ANTs) are powerful drugs that have reduced the mortality of cancer patients. However, their use is limited by the development of cardiotoxicity (CTX), which is dose dependent and may lead to left ventricular dysfunction and heart failure. Although various strategies have been suggested to reduce the negative effects of ANTs, CTX is still an important unresolved clinical issue. This may be due at least partly to the incomplete characterization of the molecular and cellular mechanisms of ANT-induced CTX. In addition, although various forms of cardiac damage have been demonstrated with the use of these drugs in experimental studies, it is not yet clear how these translate to th…

DrugAnthracyclinemedia_common.quotation_subjectLeftanthracyclines; cancer; cardiotoxicity; Cardiology and Cardiovascular MedicineDose dependenceAntineoplastic Agents030204 cardiovascular system & hematologyanthracyclineBioinformatics03 medical and health sciencesVentricular Dysfunction Left0302 clinical medicineAntibioticsNeoplasmsVentricular DysfunctionmedicinecancerHumansGenetic Predisposition to DiseaseAnthracyclinesmedia_commonHeart FailureCardiotoxicityAntibiotics AntineoplasticDose-Response Relationship Drugbusiness.industryanthracyclines cancer cardiotoxicityCancerHeartGeneral Medicinebiochemical phenomena metabolism and nutritionmedicine.diseaseAntineoplasticPathophysiologyCardiotoxicityCardiovascular Diseases030220 oncology & carcinogenesisHeart failureCardiology and Cardiovascular Medicinebusinessanthracyclines; cancer; cardiotoxicity; Anthracyclines; Antibiotics Antineoplastic; Cardiotoxicity; Heart Failure; Humans; Neoplasms; Ventricular Dysfunction LeftJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Sex differences in anthracycline-induced cardiotoxicity: the benefits of estrogens

2019

Anthracyclines are the cornerstone for many oncologic treatments, but their cardiotoxicity has been recognized for several decades. Female subjects, especially before puberty and adolescence, or after menopause, seem to be more at increased risk, with the prognostic impact of this sex issue being less consistent compared to other cardiovascular risk factors. Several studies imply that sex differences could depend on the lack of the protective effect of sex hormones against the anthracycline-initiated damage in cardiac cells, or on differential mitochondria-related oxidative gene expression. This is also reflected by the results obtained with different diagnostic methods, such as cardiovascu…

MaleCardiac & Cardiovascular SystemsMagnetic Resonance Spectroscopyand protection from anthracycline cardiotoxicitymedicine.disease_causeBioinformaticsRisk FactorsAnthracycline cardiotoxicityGender differenceGender differencesAnthracyclinesGonadal Steroid Hormones1102 Cardiorespiratory Medicine and HaematologyAMERICAN SOCIETYCardioprotectionSex CharacteristicsHeartPrognosisMitochondriaMenopauseEchocardiographyReperfusion InjuryHEART-FAILUREAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicity; Anthracyclines; Biomarkers; Cardiotonic Agents; Cardiotoxicity; Echocardiography; Female; Gonadal Steroid Hormones; Heart; Heart Failure; Humans; Magnetic Resonance Spectroscopy; Male; Mitochondria; Nuclear Medicine; Oxidative Stress; Prognosis; Reperfusion Injury; Risk Factors; Sex CharacteristicsFemaleCardiology and Cardiovascular MedicineLife Sciences & BiomedicinePOSITION PAPERCARDIAC DYSFUNCTIONCardiotonic AgentsAnthracyclineSPECKLE-TRACKINGIschemiaDRUG CARDIOTOXICITYPathophysiologymedicineHumansCHILDHOOD-CANCER SURVIVORSBREAST-CANCERPathophysiology monitoring and protection from anthracycline cardiotoxicityHeart FailureCardiotoxicityScience & Technologybusiness.industryWORKING GROUPmedicine.diseaseCardiotoxicityOxidative StressmonitoringCardiovascular System & HematologyHeart failureCardiovascular System & CardiologyRISK-FACTORSNuclear MedicinebusinessOxidative stressAnthracycline cardiotoxicity; Gender differences; Pathophysiology monitoring and protection from anthracycline cardiotoxicityBiomarkersHormone
researchProduct

Cancer cell–autonomous contribution of type I interferon signaling to the efficacy of chemotherapy

2014

International audience; The immune system is routinely confronted with cell death resulting from the physiological turnover of renewable tissues, as well as from pathological insults of several types. We hypothesize the existence of a mechanism that allows the immune system to discriminate between physiological and pathological instances of cell death, but the factors that determine whether cellular demise is perceived as a neutral, tolerogenic or immunogenic event remain unclear 1. Infectious insults are accompanied by so-called microbe-associated molecular patterns (MAMPs), i.e., viral or bacterial products that activate immune cells through a panel of pattern-recognition receptors (PRRs)…

Myxovirus Resistance ProteinsMessengerReceptor Interferon alpha-betaInbred C57BLchemotherapyInterferon alpha-betaMiceInterferonReceptorsAnthracyclinesNeoplasm MetastasisRIG-IPattern recognition receptorAdaptor ProteinsGeneral MedicineNeoadjuvant Therapy3. Good healthGene Expression Regulation NeoplasticTreatment OutcomeReceptors Pattern RecognitionInterferon Type I[SDV.IMM]Life Sciences [q-bio]/ImmunologyFemaleImmunocompetencemedicine.drugReceptorSignal TransductionBreast Neoplasms[SDV.CAN]Life Sciences [q-bio]/CancerBiologyPattern RecognitionSettore BIO/09General Biochemistry Genetics and Molecular BiologyParacrine signallingImmune systemmedicineCXCL10AnimalsHumanscancerRNA MessengerAutocrine signallingNeoplastic[SDV.IMM.IMM]Life Sciences [q-bio]/Immunology/ImmunotherapyToll-Like Receptor 3Mice Inbred C57BLVesicular TransportChemokine CXCL10Adaptor Proteins Vesicular TransportGene Expression RegulationDoxorubicinImmunologyTLR3RNAAdaptor Proteins Vesicular Transport; Animals; Anthracyclines; Breast Neoplasms; Chemokine CXCL10; Doxorubicin; Female; Gene Expression Regulation Neoplastic; Humans; Immunocompetence; Interferon Type I; Mice Inbred C57BL; Myxovirus Resistance Proteins; Neoadjuvant Therapy; Neoplasm Metastasis; RNA; RNA Messenger; Receptor Interferon alpha-beta; Receptors Pattern Recognition; Toll-Like Receptor 3; Treatment Outcome; Signal Transduction
researchProduct

Effects of phenols of extra vergin olive oil on Hl60 cell lines sensitive and resistant to anthracycline

2006

Settore BIO/14 - Farmacologiaphenols cell lines anthracycline
researchProduct

A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity: an opinion paper of the working group on drug …

2016

Anthracyclines are the mainstay of treatment of a variety of haematological malignancies and solid tumours. Unfortunately, the clinical use of these drugs is limited by cumulative, dose-related cardiotoxicity which may ultimately lead to a severe and irreversible form of cardiomyopathy. Thus, there is an increasing need for close cooperation among cardiologists, oncologists and haemato-oncologists. As anthracyclines save lives, the logical goal of this cooperation, besides preventing or mitigating cardiotoxicity, is to promote an acceptable balance between the potential cardiac side effects and the vital benefit of anticancer treatment. This manuscript, which is specifically addressed to th…

cardio-oncologymedicine.medical_treatmentCardiomyopathyheart failure030204 cardiovascular system & hematologyanthracyclines; cardio-oncology; cardiology consult; cardiotoxicity; heart failure; Anthracyclines; Antibiotics Antineoplastic; Cardiology; Cardiomyopathies; Cardiotoxicity; Humans; Italy; Neoplasms; Practice Guidelines as Topic; Societies Medical; Disease Managementanthracyclines; cardiotoxicity; heart failurecardiology consult0302 clinical medicineCardiologistsAntibioticsNeoplasmsDisease management (health)Societies Medicalmedia_commonanthracyclinesAntibiotics AntineoplasticDisease ManagementGeneral MedicineAntineoplasticItalyCardiovascular Diseases030220 oncology & carcinogenesisSupplement SubmissionPractice Guidelines as TopicCardiologyCardiomyopathiesRisk assessmentCardiology and Cardiovascular MedicineDrugmedicine.medical_specialtyAnthracyclinemedia_common.quotation_subjectCardiologycardiotoxicityanthracyclines; cardio-oncology; cardiology consult; cardiotoxicity; heart failure; Cardiology and Cardiovascular MedicineAntineoplastic AgentsanthracyclineRisk Assessment03 medical and health sciencesMedicalInternal medicinemedicineHumansIntensive care medicineCardiotoxicityChemotherapybusiness.industrymedicine.diseaseHeart failureSocietiesbusinessJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct